1. Home
  2. SHEN vs DSGN Comparison

SHEN vs DSGN Comparison

Compare SHEN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shenandoah Telecommunications Co

SHEN

Shenandoah Telecommunications Co

HOLD

Current Price

$15.96

Market Cap

878.5M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$10.48

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHEN
DSGN
Founded
1902
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
878.5M
819.6M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
SHEN
DSGN
Price
$15.96
$10.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$26.00
$15.25
AVG Volume (30 Days)
299.7K
1.1M
Earning Date
05-01-2026
04-28-2026
Dividend Yield
0.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$357,854,000.00
N/A
Revenue This Year
$7.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.08
N/A
52 Week Low
$9.67
$3.33
52 Week High
$17.35
$17.25

Technical Indicators

Market Signals
Indicator
SHEN
DSGN
Relative Strength Index (RSI) 50.03 37.06
Support Level $14.10 $9.36
Resistance Level $17.00 $10.59
Average True Range (ATR) 0.51 1.29
MACD -0.04 -0.38
Stochastic Oscillator 39.85 6.83

Price Performance

Historical Comparison
SHEN
DSGN

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: